Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Weight Watchers is Novo Nordisk's latest partnersip.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for $299 in July, a $200 Savings Offer to Improve Access as WeightWatchers’ Trusted, Science-Backed Approach Continues to Lead the Industr ...